Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis

作者：Chaturvedi Vishnu^*; Ramani Rama; Andes David; Diekema Daniel J; Pfaller Michael A; Ghannoum Mahmoud A; Knapp Cindy; Lockhart Shawn R; Ostrosky Zeichner Luis; Walsh Thomas J; Marchillo Karen; Messer Shawn; Welshenbaugh Amanda R; Bastulli Cara; Iqbal Noreen; Paetznick Victor L; Rodriguez Jose; Sein Tin

来源：Antimicrobial Agents and Chemotherapy, 2011, 55(4): 1543-1548.

DOI：10.1128/AAC.01510-09

There are few multilaboratory studies of antifungal combination testing to suggest a format for use in clinical laboratories. In the present study, eight laboratories tested quality control (QC) strain Candida parapsilosis ATCC 22019 and clinical isolates Candida albicans 20533.043, C. albicans 20464.007, Candida glabrata 20205.075, and C. parapsilosis 20580.070. The clinical isolates had relatively high azole and echinocandin MICs. A modified CLSI M27-A3 protocol was used, with 96-well custom-made plates containing checkerboard pairwise combinations of amphotericin B (AMB), anidulafungin (AND), caspofungin (CSP), micafungin (MCF), posaconazole (PSC), and voriconazole (VRC). The endpoints were scored visually and on a spectrophotometer or enzyme-linked immunosorbent assay (ELISA) reader for 50% growth reduction (50% inhibitory concentration [IC(50)]). Combination IC(50)s were used to calculate summation fractional inhibitory concentration indices (FICIs) (Sigma FIC) based on the Lowe additivity formula. The results revealed that the IC(50)s of all drug combinations were lower or equal to the IC(50) of individual drugs in the combination. A majority of the Sigma FIC values were indifferent (Sigma FIC = 0.51 to 2.0), but no antagonism was observed (Sigma FIC >= 4). Synergistic combinations (Sigma FIC <= 0.5) were found for AMB-PSC against C. glabrata and for AMB-AND and AMB-CSP against C. parapsilosis by both visual and spectrophotometric readings. Additional synergistic interactions were revealed by either of the two endpoints for AMB-AND, AMB-CSP, AMB-MCF, AMB-PSC, AMB-VRC, AND-PSC, CSP-MCF, and CSP-PSC. The percent agreements among participating laboratories ranged from 37.5% (lowest) for AND-CSP and POS-VOR to 87.5% (highest) for AMB-MCF and AND-CSP. Median Sigma FIC values showed a wide dispersion, and interlaboratory agreements were less than 85% in most instances. Additional studies are needed to improve the interlaboratory reproducibility of antifungal combination testing.

• 出版日期2011-4